Nucletron UK Ltd

Stand no.  74

Nucletron: Improving the Quality and Cost Effectiveness of Treatment for Breast Cancer and Prostate Cancer Patients

Radiotherapy and Brachytherapy Equipment and Software Manufacturers

Showcase Content

Nucletron will demonstrate Oncentra Prostate, a real-time treatment solution for minimally invasive treatment of prostate cancer that could reduce patient treatment times from 5-6 weeks to 1-2days. In addition Nucletron will showcase AccuBoost, a new but quickly adopted treatment for breast cancer that has over 30 installations in the USA and has recently been cleared for use in the UK and Europe. AccuBoost allows high quality image guided stereotactic radiotherapy to be delivered to patients at a fraction of the cost of standard radiotherapy.

Who are we targeting?

Medical Oncologists, Clinical directors, Chief Executives, Payers, Patient interest groups and charities, public and private sector health providers especially in cancer care

Why NHS staff should visit our showcase?

Staff will have the opportunity to see how small financial investments can result in major improvements in patient quality of life whilst also reducing total treatment times and improving long-term treatment outcomes. These drivers have the added benefit having a fast return on investment and are becoming the favoured treatment of choice underpinned by emerging clinical evidence.

Contact

info@uk.nucletron.com

www.nucletron.com   www.aboutbrachytherapy.com  www.treatwhatyousee.com

Partners

Christie Hospital, Manchester;  St James Institute of Oncology, Leeds; Hammersmith, London; County Hospital, Lincoln; Royal Devon and Exeter Hospital, Exeter.
  
Oncology Departments within NHS trusts in the UK have adopted Oncentra Prostate as listed above. Over 30 hospitals in the USA have adopted AccuBoost, including our main reference centres as listed above.

KOLs from these sites include Dr James Wylie (Christie), Dr Ann Henry (Leeds) and Mr Ian Mark (Lincoln). From the USA AccuBoost sites, leading KOLs include Dr. Shirin Sioshansi and Dr. David Wazer (Rhode Island Hospital), Dr Scott Ackerman (First Coast Oncology) and Dr Michael Kasper (Lynn Cancer Institute)